Reperfusion Injury vs. ST Elevation at 1 Week Post-PCI

What is reperfusion injury?

• No-reflow phenomenon (microvascular obstruction)
• Arrhythmias (particularly accelerated idioventricular rhythm and VF) occurring within the first minutes to hours of reperfusion
• Microvascular damage and cardiomyocyte death

So what causes ST elevation at ~1 week post-PCI?

1. Early post-MI pericarditis (Epistenocardiac pericarditis)

• Occurs 1–3 days after a large, transmural MI
• Caused by pericardial inflammation overlying the necrotic zone
• Rare in the primary PCI era (early reperfusion limits infarct size)
• Presents with diffuse ST elevation (saddle-shaped), pleuritic chest pain, pericardial rub
• Braunwald's Heart Disease: "It is rare in the primary PCI era and is now seen after large, transmural MIs due to absent or late/failed reperfusion."

2. Dressler syndrome (Late post-MI pericarditis)

• Occurs 1 week to a few months after MI — this is the timeframe in your question
• Immune-mediated (autoantibodies against cardiac antigens released by necrotic myocardium)
• Presents with: fever, pleuritic chest pain, pericardial rub, pericardial/pleural effusion, elevated CRP
• Can produce diffuse ST elevation on ECG (pericarditic pattern)
• Incidence has dropped dramatically in the reperfusion era (<1% of MIs)
• More common after large MIs — i.e., patients where PCI was late or failed
• Goldman-Cecil Medicine: "Pericarditis developing later (2 to 10 weeks) after acute MI could represent Dressler syndrome, which is believed to be immune mediated."

3. Stent thrombosis / re-occlusion

• Can cause recurrent ST elevation at any time post-PCI
• Acute/subacute stent thrombosis (within hours–days) or late stent thrombosis (>30 days)
• Associated with re-elevation of cardiac biomarkers and acute ischemic symptoms
• Requires emergency angiography

4. Left ventricular aneurysm

• Persistent ST elevation (weeks to months after large anterior MI) is a classic sign of LV aneurysm formation from infarct expansion
• Unlike ischemic ST elevation, this is persistent/fixed and not associated with ongoing symptoms or biomarker rise
• Confirmed with echocardiography

Summary Table

• Cover the most recent ACS guidelines and evidence available in the medical textbooks in this library (which include up-to-date sources like Harrison's 2025, Braunwald's Heart Disease, and Goldman-Cecil Medicine)
• Help you look up specific ACS topics — management, antithrombotic therapy, risk stratification, NSTEMI vs STEMI protocols, etc.

• 2021 — ACC/AHA Guideline for Coronary Artery Revascularization (replaced the 2011 CABG + 2011 PCI guidelines)
• 2022 — AHA/ACC/HFSA Guideline for Heart Failure (separate topic)
• 2023 — ACC/AHA Guideline for the Diagnosis and Management of NSTEMI/UA (Non-ST-Elevation Acute Coronary Syndromes) — this was a significant focused update
• 2023 — AHA/ACC updates on antithrombotic therapy in ACS

• ACC.org
• AHA Professional Heart Daily
• Circulation journal

1. REDUCE-AMI (2024): Beta-blockers may not be needed post-STEMI with preserved EF — challenges 30+ years of standard practice
2. Complete revascularization in STEMI (COMPLETE trial) — now Class I
3. Colchicine post-MI (COLCOT, LoDoCo2) — now Class IIa for secondary prevention
4. DAPT de-escalation/abbreviation — shorter courses with P2Y12 monotherapy increasingly supported
5. PCSK9 inhibitors in all very-high-risk ACS patients not at LDL goal
6. Culprit-only PCI in cardiogenic shock (CULPRIT-SHOCK) — not multivessel at index procedure

Why UFH is Preferred Over Enoxaparin During PCI

1. Real-Time Monitoring with ACT (Activated Clotting Time)

• UFH anticoagulant effect can be monitored at the bedside in the cath lab using ACT
• Target ACT during PCI: 250–350 seconds (or 200–250s if GP IIb/IIIa inhibitor used)
• Enoxaparin has no reliable point-of-care monitoring tool — anti-Xa levels require a lab and take time; not practical during an active procedure
• This real-time titratability is critical during a procedure where over- or under-anticoagulation can have immediate consequences

2. Rapid, Complete Reversibility with Protamine

• UFH is fully reversible with protamine sulfate within minutes — essential if:
  • Arterial access site bleeding occurs
  • Emergency CABG is needed
  • Tamponade or perforation develops during the procedure
• Protamine only partially reverses enoxaparin (~60% of anti-IIa activity, poor reversal of anti-Xa activity) — making it unreliable in urgent bleeding situations

3. Dose Titration During the Procedure

• UFH can be redosed in real time based on ACT measurements
• Enoxaparin has a fixed subcutaneous or weight-based IV dosing with a prolonged half-life (~4–6 hours) — difficult to adjust during a procedure

4. Predictable Pharmacokinetics in the Cath Lab Context

• If the patient received enoxaparin pre-procedure (e.g., in NSTEMI management), the residual anti-Xa level is unknown at the time of PCI
• Guidelines (ESC, ACC/AHA) recommend:
  • If last enoxaparin dose <8h ago → no additional anticoagulant needed
  • If last dose 8–12h ago → additional 0.3 mg/kg IV enoxaparin
  • If last dose >12h ago → treat as if no anticoagulation
• This complexity contrasts with UFH, where you simply dose by weight and check ACT

5. Short Half-Life

• UFH IV half-life: ~1 hour (dose-dependent)
• Enoxaparin half-life: ~4–6 hours
• Shorter half-life means anticoagulation wears off quickly after sheath removal → lower risk of access site hematoma and major bleeding post-procedure

Summary Table

Is Enoxaparin Ever Used in PCI?

• It was already started pre-procedure for ACS management
• Operator preference / institutional protocol
• ATOLL trial showed non-inferior outcomes with IV enoxaparin vs. UFH in STEMI-PCI